Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment

Pharmaceutical Research

Volumn 28, Issue 4, 2011, Pages 762-775

  Wauthoz, Nathalie ^a   Deleuze, Philippe ^a   Saumet, Amandine ^a   Duret, Christophe ^a   Kiss, Robert ^a   Amighi, Karim ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

Author keywords

aerosol chemotherapy; DPI; lung cancer; pulmonary delivery; temozolomide

Indexed keywords

2 PROPANOL; NIFEDIPINE; TEMOZOLOMIDE; TOBRAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DETERMINATION; DRUG FORMULATION; DRUG MEGADOSE; DRY POWDER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIGHT SCATTERING; LUNG CANCER; METERED DOSE INHALER; MOISTURE; MORPHOLOGY; MOUSE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; THERMOGRAVIMETRY; X RAY DIFFRACTION;

ADMINISTRATION, INHALATION; ANTINEOPLASTIC AGENTS, ALKYLATING; DACARBAZINE; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EXCIPIENTS; HUMANS; LUNG NEOPLASMS; MICROSCOPY, ELECTRON, SCANNING; MODELS, THEORETICAL; PARTICLE SIZE; POWDERS; SOLUBILITY; SURFACE PROPERTIES;

EID: 79955602334     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0329-x     Document Type: Article

References (42)

1. A Jemal MJ Thun LAG Ries HL Howe HK Weir MM Center E Ward X-C Wu C Eheman R Anderson UA Ajani B Kohler BK Edwards 2008 Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control J Natl Cancer Inst 100 1672 1694 19033571 10.1093/jnci/djn389
2. JR Molina P Yang SD Cassivi SE Schild AA Adjei 2008 Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship Mayo Clin Proc 83 584 594 18452692 10.4065/83.5.584 (Pubitemid 351720831)
3. L Erhunmwunsee T D'Amico 2009 Surgical management of pulmonary metastases Ann Thorac Surg 88 2052 2060 19932302 10.1016/j.athoracsur.2009.08.033
4. T Yano F Shoji Y Maehara 2009 Current status of pulmonary metastasectomy from primary epithelial tumours Surg Today 39 91 97 19198984 10.1007/s00595-008-3820-9
5. Smyth HDC, Saleem I, Donovan M, Verschraegen CF. Pulmonary delivery of anti-cancer agents. In: Williams RO, Taft DR, McConville JT, editors. Advanced drug formulation design to optimize therapeutic outcomes. New-York: Informa Healthcare; 2008. p. 81-111.
6. S Sharma D White AR Imondi ME Placke DM Vail MG Kris 2001 Development of inhalational agents for oncologic use Am J Clin Oncol 19 1839 1847 1:CAS:528:DC%2BD3MXisFygsL0%3D (Pubitemid 32230887)
7. KK Jain 2008 Drug delivery systems-an overview Methods Mol Biol 437 1 50 18369961 10.1007/978-1-59745-210-6-1 1:CAS:528:DC%2BD1cXkslOhtLs%3D
8. IT Shevchenko GE Resnik 1968 Inhalation of chemical substances and oxygen in radiotherapy of bronchial cancer Neoplasia 15 419 426 1:STN:280: DyaF1M%2Fhtlyntg%3D%3D
9. AH Limper 2004 Chemotherapy-induced lung disease Clin Chest Med 25 53 64 15062597 10.1016/S0272-5231(03)00123-0 (Pubitemid 38296331)
10. F Gagnadoux J Hureaux L Vecellio T Urban A Le Pape I Valo J Montharu V Leblond M Boisdron-celle S Lerondel C Majoral P Diot JL Racineux E Lemarie 2008 Aerosolized chemotherapy J Aerosol Med Pulm Drug Deliv 21 61 69 18518832 10.1089/jamp.2007.0656 1:CAS:528:DC%2BD1cXjvFeiu78%3D
11. BPH Wittgen PWA Kunst K van der Born AW van Wijk W Perkins FG Pilkiewicz R Perez-Soler S Nicholson GJ Peters PE Postmus 2007 Phase I study of aerosolized SLIT cisplatine in the treatment of patients with carcinoma of the lung Clin Cancer Res 13 2414 2421 17438100 10.1158/1078-0432.CCR-06-1480 1:CAS:528:DC%2BD2sXkt1enu70%3D (Pubitemid 46698592)
12. GA Otterson MA Villalona-Calero S Sharma MG Kris A Imondi M Gerber DA White MJ Ratain JH Schiller A Sandler M Kraut S Mani JR Murren 2007 Phase I study of inhaled doxorubicin for patients with metastatic tumors to the lungs Clin Cancer Res 13 1246 1252 17317836 10.1158/1078-0432.CCR-06-1096 1:CAS:528:DC%2BD2sXhvF2htr4%3D (Pubitemid 46424066)
13. CF Verschraegen BE Gilbert E Loyer A Huaringa G Walsh RA Newman V Knight 2004 Clinical evaluation of the delivery and safety of aerosolized liposomal 9-nitro-20(S)-Camptothecin in patients with advanced pulmonary malignancies Clin Cancer Res 10 2319 2326 15073107 10.1158/1078-0432.CCR-0929-3 1:CAS:528:DC%2BD2cXivFSqsrc%3D (Pubitemid 38445689)
14. C O'Callaghan PW Barry 1997 The science of nebulised drug delivery Thorax 52 S31 S44 9155849 10.1136/thx.52.2008.S31
15. G Pilcer K Amighi 2010 Formulation strategy and use of excipients in pulmonary drug delivery Int J Pharm 392 1 19 20223286 10.1016/j.ijpharm.2010.03. 017 1:CAS:528:DC%2BC3cXmtVGku7g%3D
16. C Kleinstreuer Z Zhang 2003 Targeted drug aerosol deposition analysis for a four-generation lung airway model with hemispherical tumors J Biomech Eng 125 197 206 12751281 10.1115/1.1543548 1:STN:280:DC%2BD3s3jtVSnsg%3D%3D (Pubitemid 36506133)
17. Cancellieri A, Dalpiaz G, Maffessanti M, Pesci A, Polverosi R, Zompatori M. Diffuse Lung Diseases, clinical features, pathology, HRCT. New York: Springer; 2006.
18. F Lefranc V Facchini R Kiss 2007 Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas Oncologist 12 1395 1403 18165616 10.1634/theoncologist.12-12-1395 1:CAS:528:DC%2BD1cXhslSntLk%3D
19. VA Trinh SP Pastel WJ Hwu 2009 The safety of temozolomide in the treatment of malignancies Expert Opin Drug Saf 8 493 499 19435405 10.1517/14740330902918281 1:CAS:528:DC%2BD1MXns1CgsLw%3D
20. F Maldonado AH Limper KL Kaiser M-C Aubry 2007 Temozolomide-associated organizing pneumonitis Mayo Clin Proc 82 771 773 17550757 10.4065/82.6.771 (Pubitemid 46878100)
21. CS Adonizio JS Babb C Maiale C Huang J Donahue MM Millenson M Hosford R Somer J Treat E Sherman CJ Langer 2002 Temozolomide in non-small-cell lung cancer: preliminary results of a phase II trial in previously treated patients Clin Lung Cancer 3 254 258 14662033 10.3816/CLC.2002.n.009 1:CAS:528: DC%2BD38XnvVSms70%3D (Pubitemid 34752670)
22. NW Choong AM Mauer PC Hoffman CM Rudin JD Winegarden JL Villano M Kozloff JL Wade DF Sciortino L Szeto EE Vokes 2006 Phase II trial of temozolomide and irinotecan as second line treatment for advanced non-small cell lung cancer J Thorac Oncol 1 732 733 10.1097/01243894-200609000-00026
23. C Kouroussis L Vamvakas N Vardakis A Ktsakis K Kalbakis Z Saridakis N Kentepozidis S Giassas V Georgoulias 2009 Continuous administration of daily low-dose temozolomide in pretreated patients with advanced non-small cell lung cancer: a phase II study Oncology 76 112 117 19142045 10.1159/000192586 1:CAS:528:DC%2BD1MXhsFKksLw%3D
24. D Lamoral-Theys L Pottier F Kerff F Dufrasne F Proutière N Wauthoz P Neven L Ingrassia P Van Antwerpen F Lefranc M Gelbcke B Pirotte JL Kraus A Kornienko R Kiss J Dubois 2010 Simple di- and trivanillates exibit cytostatic properties towards cancer cells resistant to pro-apoptotic stimuli Bioorg Med Chem 18 3823 3833 20466556 10.1016/j.bmc.2010.04.047 1:CAS:528: DC%2BC3cXmslOisrg%3D
25. N Wauthoz P Deleuze J Hecq I Roland S Saussez I Adanja O Debeir C Decaestecker V Mathieu R Kiss K Amighi 2010 In vivo assessment of témozolomide local delivery for lung cancer inhalation therapy Eur J Pharm Sci 29 402 411 10.1016/j.ejps.2010.01.010
26. V Mathieu M Le Mercier N De Neve S Sauvage T Gras I Roland F Lefranc R Kiss 2007 Galectin-1 knockdown increases sensitivity of temozlomide in a B16F10 mouse metastatic melanoma model J Invest Dermatol 127 2399 2410 17495956 10.1038/sj.jid.5700869 1:CAS:528:DC%2BD2sXhtVeisb7F (Pubitemid 47619747)
27. S Sdraulig R Franich RA Tinker S Solomon R O'Brien PN Johnston 2008 In vitro dissolution studies of uranium bearing material in simulated lung fluid J Environ Radioact 99 527 538 17949865 10.1016/j.jenvrad.2007.08.009 1:CAS:528:DC%2BD1cXjtFShtrc%3D (Pubitemid 351312832)
28. VP Shah Y Tsong P Sathe J-P Liu 1998 In vitro dissolution profile comparison-statistics and analysis of the similarity factor f2 Pharm Res 15 889 896 9647355 10.1023/A:1011976615750 1:CAS:528:DyaK1cXjvFWltrw%3D (Pubitemid 28307831)
29. R Stupp PM Warren MJ van den Bent M Weller B Fisher MJB Taphoorn K Belanger AA Brandes Ch Marosi U Bogdahn J Curschmann RC Janzer SK Ludwin T Gorlia A Allgeier D Lacombe JG Cairncross E Eisenhauer R Mirimanoff 2005 Radiotherapy plus concomitant and adjuvant temozolomide for glioblastomas N Engl J Med 352 987 996 15758009 10.1056/NEJMoa043330 1:CAS:528:DC%2BD2MXit1Wksbk%3D (Pubitemid 40349501)
30. J Hecq M Deleers D Fanara H Vrancks K Amighi 2005 Preparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipine Int J Pharm 299 167 177 15996838 10.1016/j.ijpharm.2005.05.014 1:CAS:528:DC%2BD2MXmtFSgs78%3D (Pubitemid 40962418)
31. G Pilcer F Vanderbist K Amighi 2009 Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery Int J Pharm 365 162 169 18782609 10.1016/j.ijpharm.2008.08.014 1:CAS:528:DC%2BD1cXhsVKnur7L
32. S Miao YH Ross 2005 Crystallization kinetics and X-ray diffraction of crystals formed in amorphous lactose, threhalose, and lactose/trehalose mixtures J Food Sci 70 350 358 10.1111/j.1365-2621.2005.tb09976.x
33. G Pilcer T Sebti K Amighi 2006 Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation Pharm Res 23 931 940 16715383 10.1007/s11095-006-9789-4 1:CAS:528:DC%2BD28XkslKjtr0%3D (Pubitemid 43781401)
34. Sebti T. Developpement et evaluation de formulations lipidiques à poudre sèche pour inhalation, Thèse (ULB, Pharmacie). Bruxelles: Université Libre de Bruxelles; 2006.
35. N Drapier-Beche J Fanni M Parmentier M Vilasi 1997 Evaluation of lactose crystalline forms by nondestructive analysis J Dairy Sci 80 457 463 10.3168/jds.S0022-0302(97)75957-5 1:CAS:528:DyaK2sXit1yrur8%3D
36. JC Sung BL Pulliam DA Edwards 2007 Nanoparticles for drug delivery to the lungs Trends Biotechnol 25 563 570 17997181 10.1016/j.tibtech.2007.09.005 1:CAS:528:DC%2BD2sXhtlCru7nK (Pubitemid 350138179)
37. NM Davies MR Feddah 2003 A novel method for assessing dissolution of aerosol inhaler products Int J Pharm 255 175 187 12672613 10.1016/S0378-5173(03) 00091-7 1:CAS:528:DC%2BD3sXisVGksL4%3D (Pubitemid 36369601)
38. A Henning M Schneider N Nafee L Muijs E Rytting X Wang T Kissel D Grafahrend D Klee M Lehr 2010 Influence of particle size and material properties on mucociliary clearance from the airways J Aerosol Med Pulm Drug Deliv 23 233 241 20500091 10.1089/jamp.2009.0806 1:CAS:528:DC%2BC3cXpvFSqtLs%3D
39. W Yang J Tam DA Miller J Zhou JT McConville KP Johnston RO Williams 2008 High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers Int J Pharm 361 177 188 18556158 10.1016/j.ijpharm. 2008.05.003 1:CAS:528:DC%2BD1cXpt1alsr8%3D
40. JH Sampson GE Archer AT Villavicencio RE McLendon AH Friedman WR Bishop DD Bigner HS Friedman 1999 Treatment of neoplastic meningitis with intrathecal temozolomide Clin Cancer Res 5 1183 1188 10353755 1:CAS:528:DyaK1MXjslKltLc%3D (Pubitemid 29233236)
41. RO Salama T Daniela HK Chan PM Young 2008 Preparation and characterisation of controlled release co-spray dried drug-polymer microparticles for inhalation 2: evaluation of in vitro release profiling methodologies for controlled release respiratory aerosols Eur J Pharm Biopharm 70 145 152 18534832 10.1016/j.ejpb.2008.04.009 1:CAS:528:DC%2BD1cXhtVOitrjM
42. Y-J Son JT McConville 2009 Development of a standardized dissolution test method for inhaled pharmaceutical formulations Int J Pharm 382 15 22 19665533 10.1016/j.ijpharm.2009.07.034 1:CAS:528:DC%2BD1MXhtlSltbfM